Constipation News and Research RSS Feed - Constipation News and Research

Constipation is a condition in which stool becomes hard, dry, and difficult to pass, and bowel movements don’t happen very often. Other symptoms may include painful bowel movements, and feeling bloated, uncomfortable, and sluggish.
Low-FODMAP rye bread may reduce symptoms of IBS

Low-FODMAP rye bread may reduce symptoms of IBS

Patients with irritable bowel syndrome (IBS) are often concerned that certain foods may trigger or worsen their symptoms, which can include abdominal pain, diarrhea, or constipation. In a new study, patients who ate rye bread that was low in so-called "FODMAPs" (fermentable oligo- di- and mono-saccharides and polyols) experienced milder IBS symptoms than patients who ate normal rye bread. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Treatment for IBS proves difficult, survey reveals

Treatment for IBS proves difficult, survey reveals

A new national survey by Health Union of more than 1,000 individuals with Irritable Bowel Syndrome (IBS) reveals that the condition is difficult to diagnose and often even more difficult to treat. [More]
Food's transit time through colon affects health of digestive system

Food's transit time through colon affects health of digestive system

The time it takes for ingested food to travel through the human gut - also called transit time - affects the amount of harmful degradation products produced along the way. [More]
Researchers play crucial role in crafting diagnostic criteria for functional GI disorders

Researchers play crucial role in crafting diagnostic criteria for functional GI disorders

With no laboratory test available to diagnose functional gastrointestinal disorders, proper diagnostic criteria are critical for clinicians to make an accurate determination of what ails their patients. [More]
FDA approves novel stomach-draining device to treat obesity

FDA approves novel stomach-draining device to treat obesity

The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal. [More]
PD surgery improves quality of life in patients with malignant pleural mesothelioma

PD surgery improves quality of life in patients with malignant pleural mesothelioma

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life. [More]
Metabolite of oral DMF drug for multiple sclerosis appears to slow onset of Parkinson's disease

Metabolite of oral DMF drug for multiple sclerosis appears to slow onset of Parkinson's disease

The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson's disease, researchers say. [More]
Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Data presented today at the American Society of Clinical Oncology congress showed that cabozantinib, a next generation tyrosine kinase inhibitor (TKI) can extend the lives of patients by nearly two years following failure of one or more anti-angiogenic therapies almost five months longer than everolimus, a current standard of care therapy. [More]
Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spiders have helped researchers from Australia and the US discover a new target for irritable bowel syndrome pain. [More]
New research explores women’s perspective about medication use during pregnancy

New research explores women’s perspective about medication use during pregnancy

Pregnant women overestimate the risks of taking over the counter and prescribed medication - according to new research from the University of East Anglia. [More]
Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA. [More]
Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

A child feels nauseated all the time, but no medical test can find what is wrong. Or a child vomits regularly, but there's no illness or eating disorder to explain it. These, and other stomach and bowel-related problems with no obvious causes, are called functional gastrointestinal disorders. [More]
Experts discuss new insights into early stages of Parkinson’s disease at EAN Congress

Experts discuss new insights into early stages of Parkinson’s disease at EAN Congress

Early diagnosis and starting treatment as early as possible are decisive factors in achieving improved quality of life for Parkinson's sufferers. Experts are discussing a wide range of new insights into the early stages of the disease at the Congress of the European Academy of Neurology in Copenhagen. [More]
First buprenorphine implant for opioid dependence treatment gets FDA approval

First buprenorphine implant for opioid dependence treatment gets FDA approval

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program. [More]
Regular use of laxatives may flatten rigidity found in Parkinson's disease

Regular use of laxatives may flatten rigidity found in Parkinson's disease

In a recent retrospective analysis, investigators discovered that the year-on-year increase in rigidity found in Parkinson's disease flattened off with the regular use of laxatives to manage constipation. [More]
Tecentriq drug gets FDA approval to treat urothelial carcinoma

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer. [More]
Studies show mango consumption may contribute to protective health effects

Studies show mango consumption may contribute to protective health effects

Four new studies surrounding the effects of mango consumption suggest this superfruit has the potential to help combat adverse effects associated with high fat diets and obesity (animal study), as well inhibit growth of fat cells (anti-lipogenic properties in an in-vivo study), slow advancement of breast cancer tumors (animal study), as well as improve regularity and decrease inflammation associated with constipation (human subject study). [More]
Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease. [More]
LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center. [More]
Advertisement